Compare QUBT & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QUBT | AAPG |
|---|---|---|
| Founded | 2001 | 2009 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2019 | 2024 |
| Metric | QUBT | AAPG |
|---|---|---|
| Price | $8.57 | $14.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $17.50 | ★ $48.40 |
| AVG Volume (30 Days) | ★ 6.0M | 4.3K |
| Earning Date | 05-13-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 84.93 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $682,000.00 | N/A |
| Revenue This Year | $3,210.56 | $290.34 |
| Revenue Next Year | $51.26 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 82.84 | N/A |
| 52 Week Low | $6.18 | $14.81 |
| 52 Week High | $25.84 | $40.47 |
| Indicator | QUBT | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 52.30 | 36.69 |
| Support Level | $7.72 | N/A |
| Resistance Level | $9.25 | $18.96 |
| Average True Range (ATR) | 0.37 | 0.26 |
| MACD | 0.10 | -0.08 |
| Stochastic Oscillator | 48.36 | 15.26 |
Quantum Computing Inc is an integrated photonics and non-linear quantum optics company to develop and deliver machines for quantum computing, reservoir computing, and remote sensing, imaging, and cybersecurity applications based on patented and proprietary photonics technology. Its products are designed to operate at room temperature and low power at an affordable cost. The Company's portfolio of core technologies and products offers capabilities in the areas of high-performance computing, artificial intelligence, and cybersecurity, as well as remote sensing applications.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.